This trial demonstrated that once-weekly administration of the highest dose of a unimolecular triple-agonist (GLP1RAGIPRAGCGRA) by subcutaneous injection in people with obesity and T2DM induces weight loss that appears comparable to that achieved with bariatric surgery, with a favourable safety and tolerability profile
doi: 10.1126/sciadv.1400121 226 NaculLde BarrosBKingdonCCCliffJMClarkTGMudieKet al
Several profiles tend to respond well: Adults over 45 whose natural glutathione synthesis declines with age, since aging reduces the enzymes responsible for production
Neumann, M., Kwong, L
A: Multiple pathways: GH receptor upregulation, nitric oxide system modulation, VEGF-promoted angiogenesis, and direct inflammatory cytokine interaction
The suspension was centrifuged at 1000 rcf for 3 min, and the cell pellet was resuspended in tissue-specific culture media, including Advanced DMEM/F-12 (Gibco, 12634028) with glutamax (Invitrogen, 35050061), B27 (Gibco, 17504044), 1.25 mM N-acetylcysteine (Macklin, N800425), 50 ng/mL Recombinant Human EGF (R&D, 236-EG-01M), 100 ng/mL Recombinant Human FGF-10 (Peprotech, 100-26-5), 100 ng/mL Recombinant Human FGF-4 (Peprotech, 100-31-25), 100 ng/mL Recombinant Human Noggin (R&D, 6057-NG), 10 M SB202190 (R&D, 1264), 250 nM CHIR99021 (Sigma, SML1046), anti-mouse CD16/32, 10 M Y-27632 (APExBIO, A3008), and 500 nM A 83-01(MCE, HY-10432)
